Related Experiment Videos
In vitro screening of nucleoside analog combinations for potential use in anti-HIV therapy
G J Veal1, M G Barry, S H Khoo
1Department of Pharmacology and Therapeutics, University of Liverpool, UK.
Abstract:
With the results from the Delta and ACTG 175 clinical trials clearly showing an increased benefit of two drugs over monotherapy, combination nucleoside analog therapy looks set to play a major role in the battle against HIV. It is therefore essential that suitable combinations of drugs are used in clinical trials. We investigated the intracellular activation of zidovudine (ZDV), zalcitabine (ddC), and lamivudine (3TC) in MOLT-4 cells in two- and three-drug combinations at clinically achieved concentrations. The phosphorylation of ZDV and 3TC to their active triphosphate anabolites was not affected by the presence of the other drugs studied. However, the phosphorylation of ddC was significantly inhibited when incubated with 3TC, resulting in levels of ddC triphosphate (ddC-TP) less than 50% of control values. This can be explained by the requirement of both nucleoside analogs for the enzyme deoxycytidine kinase to carry out the initial step in their phosphorylation pathways, and by the comparatively low plasma concentrations of ddC achieved in vivo. These results suggest that regimens containing nucleoside analogs should be designed taking into account potential interactions affecting phosphorylation.
Insights
Combination nucleoside analog therapy is crucial for HIV treatment. However, lamivudine (3TC) significantly inhibits zalcitabine (ddC) activation, reducing its effectiveness. Careful drug combination design is essential for optimal HIV treatment outcomes.
Area of Science:
- Pharmacology
- Virology
- Biochemistry
Background:
- Combination nucleoside analog therapy shows promise for HIV treatment, building on findings from Delta and ACTG 175 trials.
- Optimizing drug combinations is critical for effective HIV management and clinical trial design.
Purpose of the Study:
- To investigate the intracellular activation of zidovudine (ZDV), zalcitabine (ddC), and lamivudine (3TC) in combination.
- To assess potential drug-drug interactions affecting nucleoside analog phosphorylation in HIV therapy.
Main Methods:
- MOLT-4 cells were used to study two- and three-drug combinations of ZDV, ddC, and 3TC at clinically relevant concentrations.
- Intracellular phosphorylation of nucleoside analogs to their active triphosphate forms was quantified.
Main Results:
- Phosphorylation of ZDV and 3TC to active anabolites was unaffected by co-administration with other studied drugs.
- Phosphorylation of ddC was significantly inhibited by 3TC, reducing ddC triphosphate (ddC-TP) levels by over 50%.
- This inhibition is attributed to the shared requirement for deoxycytidine kinase and low in vivo ddC plasma concentrations.
Conclusions:
- Drug regimens containing nucleoside analogs require careful design to account for potential phosphorylation interactions.
- The interaction between ddC and 3TC highlights the importance of understanding intracellular drug metabolism for HIV treatment.